Seres Therapeutics (MCRB)
Develops oral bacterial consortia for infection, immune, and inflammatory conditions.
Something off on this page? Send us feedback.
Develops orally administered live biotherapeutic candidates—defined bacterial compositions intended to alter gut-microbiome functions—for vulnerable patients with inflammatory, immune, and infection-related conditions. Following the sale of VOWST, it is a U.S.-centered clinical-stage business supported by grants and prospective collaboration, licensing, and milestone capital.
Develops orally administered live biotherapeutic products: defined bacterial compositions designed to alter gastrointestinal-microbiome functions in medically vulnerable patients. Its portfolio centers on SER-155, a clinical candidate for infection-related and immune conditions, alongside preclinical SER-603 for inflammatory bowel disease and SER-147 for infection prevention in chronic liver disease.
Operates as a U.S.-centered, consolidated clinical-stage business after selling VOWST to Nestlé. It selects bacterial consortia and advances translational and clinical studies, with grants, investigator-sponsored work, and potential collaborations supporting development. No owned product is approved; advancement of the planned SER-155 study and the earlier pipeline depends on external funding, partners, clinical-trial providers, manufacturing providers, and regulatory acceptance.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Jun 23, 2026 | H.C. Wainwright | Initiate | Buy | $12 | |
| May 8, 2025 | Chardan Capital | Downgrade | Buy | Neutral | |
| Oct 24, 2024 | JP Morgan | Downgrade | Neutral | Underweight |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $15.6M · Total debt $56.6M · Total assets $101.6M · Shareholders' equity $34.5M
- Revenue
- $736.0K
- Operating income
- −$21.3M
- Net income
- $4.6M
No dividends on record.
| Institutions36 holders · as of Mar 31, 2026 | 23.82% | 2.31M shares | |
| Insiders6 holders · as of Aug 18, 2026 | 0.49% | 47.8K shares | |
| Strategic holders1 holder · as of Oct 2, 2024 | 11.30% | 1.09M shares | |
| Otherremainder | 64.39% | 6.24M shares |
9.68M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Flagship Pioneering Inc.Institution | 11.94% | 1.16M | 13Fas of Mar 31, 2026 |
Nestle SAStrategic10 percent owner | 11.30% | 1.09M | Form 4filed Oct 2, 2024 ↗ |
Vanguard Capital Management LLCInstitution | 3.04% | 294,143 | 13Fas of Mar 31, 2026 |
Marshall Wace, LLPInstitution | 1.44% | 139,539 | 13Fas of Mar 31, 2026 |
Vontobel Holding Ltd.Institution | 1.43% | 138,468 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Kelly Brady | officer: See Remarks | −64 | $4.55 |
| Aug 17, 2026 | Eric D. Shaff | director | −263 | $4.55 |
| Aug 17, 2026 | Thomas DesRosier | officer: See Remarks | −82 | $4.55 |
| Aug 17, 2026 | Matthew R. Henn | officer: See Remarks | −81 | $4.55 |
| May 18, 2026 | Matthew R. Henn | officer: See Remarks | −77 | $7.53 |
- Takeda (ADR)
Gut-selective alternative in IBD and refractory irEC.
- Johnson & Johnson
Leading biologic IBD franchise across UC and Crohn's.
- AbbVie
Blockbuster IBD therapies in both UC and Crohn's.
- Pfizer
Established anti-TNF biosimilar alternative in IBD.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Seres Therapeutics | $5.35 | −2.90% | $53.6M | — | — | 28.5 | — |
| Takeda (ADR) | $18.64 | +1.06% | $58.65B | 51.2 | 56.6 | 2.0 | +5.8% |
| Johnson & Johnson | $274.75 | −0.18% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| AbbVie | $262.35 | +0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Pfizer | $29.00 | −0.10% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Median | 44.8 | 20.2 | 4.7 | +6.2% |